DK3172233T3 - Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer - Google Patents
Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer Download PDFInfo
- Publication number
- DK3172233T3 DK3172233T3 DK15744834T DK15744834T DK3172233T3 DK 3172233 T3 DK3172233 T3 DK 3172233T3 DK 15744834 T DK15744834 T DK 15744834T DK 15744834 T DK15744834 T DK 15744834T DK 3172233 T3 DK3172233 T3 DK 3172233T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- procedures
- compositions containing
- containing anti
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462027637P | 2014-07-22 | 2014-07-22 | |
| PCT/US2015/041192 WO2016014434A2 (en) | 2014-07-22 | 2015-07-20 | Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3172233T3 true DK3172233T3 (da) | 2019-11-11 |
Family
ID=53762391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15744834T DK3172233T3 (da) | 2014-07-22 | 2015-07-20 | Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10975150B2 (da) |
| EP (2) | EP3708227A1 (da) |
| DK (1) | DK3172233T3 (da) |
| ES (1) | ES2753551T3 (da) |
| WO (1) | WO2016014434A2 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2859017T3 (da) | 2012-06-08 | 2019-05-13 | Sutro Biopharma Inc | Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf |
| ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
| US9809664B2 (en) | 2015-06-05 | 2017-11-07 | Exxonmobil Chemical Patents Inc. | Bimodal propylene polymers and sequential polymerization |
| CN107922537B (zh) | 2015-06-05 | 2021-07-27 | 埃克森美孚化学专利公司 | 气相或淤浆相中多相聚合物的制备 |
| US10329360B2 (en) | 2015-06-05 | 2019-06-25 | Exxonmobil Chemical Patents Inc. | Catalyst system comprising supported alumoxane and unsupported alumoxane particles |
| US10759886B2 (en) | 2015-06-05 | 2020-09-01 | Exxonmobil Chemical Patents Inc. | Single reactor production of polymers in gas or slurry phase |
| US9738779B2 (en) | 2015-06-05 | 2017-08-22 | Exxonmobil Chemical Patents Inc. | Heterophasic copolymers and sequential polymerization |
| US10280235B2 (en) | 2015-06-05 | 2019-05-07 | Exxonmobil Chemical Patents Inc. | Catalyst system containing high surface area supports and sequential polymerization to produce heterophasic polymers |
| WO2017132617A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
| US11059918B2 (en) | 2016-05-27 | 2021-07-13 | Exxonmobil Chemical Patents Inc. | Metallocene catalyst compositions and polymerization process therewith |
| EP3472197A1 (en) | 2016-06-15 | 2019-04-24 | Sutro Biopharma, Inc. | Antibodies with engineered ch2 domains, compositions thereof and methods of using the same |
| US11046764B2 (en) | 2017-01-03 | 2021-06-29 | Trellis Bioscience, Llc | Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3 |
| EP3658588A1 (en) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
| ES2944837T3 (es) | 2018-11-08 | 2023-06-26 | Sutro Biopharma Inc | Cepas de E. coli con citoplasma oxidativo |
| JP2023544254A (ja) | 2020-09-14 | 2023-10-23 | ストロ バイオファーマ， インコーポレイテッド | 無細胞タンパク質合成系を用いた抗体の大規模産生方法 |
| WO2022170126A2 (en) * | 2021-02-05 | 2022-08-11 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus s protein and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5869644A (en) | 1992-04-15 | 1999-02-09 | The Johns Hopkins University | Synthesis of diverse and useful collections of oligonucleotidies |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US7829064B2 (en) * | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
| US20030119056A1 (en) | 2000-12-18 | 2003-06-26 | Ladner Robert Charles | Focused libraries of genetic packages |
| EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| BRPI0816785A2 (pt) | 2007-09-14 | 2017-05-02 | Adimab Inc | bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas |
| RU2636029C2 (ru) * | 2011-02-01 | 2017-11-17 | Генмаб А/С | Человеческие антитела и конъюгаты антитело-препарат против cd74 |
-
2015
- 2015-07-20 US US15/327,601 patent/US10975150B2/en active Active
- 2015-07-20 EP EP19196549.0A patent/EP3708227A1/en active Pending
- 2015-07-20 EP EP15744834.1A patent/EP3172233B1/en active Active
- 2015-07-20 DK DK15744834T patent/DK3172233T3/da active
- 2015-07-20 WO PCT/US2015/041192 patent/WO2016014434A2/en active Application Filing
- 2015-07-20 ES ES15744834T patent/ES2753551T3/es active Active
-
2021
- 2021-03-09 US US17/196,026 patent/US20210284739A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170253656A1 (en) | 2017-09-07 |
| US10975150B2 (en) | 2021-04-13 |
| EP3708227A1 (en) | 2020-09-16 |
| EP3172233B1 (en) | 2019-09-11 |
| WO2016014434A2 (en) | 2016-01-28 |
| ES2753551T3 (es) | 2020-04-13 |
| WO2016014434A3 (en) | 2016-03-17 |
| EP3172233A2 (en) | 2017-05-31 |
| US20210284739A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3172233T3 (da) | Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer | |
| DK3386534T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| DK3303394T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3247371T3 (da) | Fremgangsmåder til oprensning af cannabinoider, sammensætninger og kits dertil | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3191421T3 (da) | Glassammensætninger, glassammensætninger til fremstilling af glasfibre og glasfibre fremstillet deraf | |
| DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
| DK3092256T3 (da) | Forbindelser og sammensætninger til immunterapi | |
| DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3166968T3 (da) | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3232872T3 (da) | System til tilberedning af drikkevarer | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3757214T3 (da) | Sammensætninger til modulering af sod-1-ekspression | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3262008T3 (da) | Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| DK2924093T3 (da) | Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse | |
| DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |